TNF blockers control psoriatic arthritis

San Francisco - Both tumor necrosis factor (TNF) blockers etanercept and infliximab continue to play an emerging role in the treatment of psoriatic arthritis (PsA), according to two new studies presented at the American College of Rheumatology annual meeting here.

Related Videos
Related Content

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023
© 2023 MJH Life Sciences

All rights reserved.